Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
Köster, Luisa-Sophie
Carbon, Maren
and
Correll, Christoph U
2014.
Emerging drugs for schizophrenia: an update.
Expert Opinion on Emerging Drugs,
Vol. 19,
Issue. 4,
p.
511.
Opler, Lewis A.
Medalia, Alice
Opler, Mark G.
and
Stahl, Stephen M.
2014.
Pharmacotherapy of cognitive deficits in schizophrenia.
CNS Spectrums,
Vol. 19,
Issue. 2,
p.
142.
Chłoń-Rzepa, Grażyna
Bucki, Adam
Kołaczkowski, Marcin
Partyka, Anna
Jastrzębska-Więsek, Magdalena
Satała, Grzegorz
Bojarski, Andrzej J.
Kalinowska-Tłuścik, Justyna
Kazek, Grzegorz
Mordyl, Barbara
Głuch-Lutwin, Monika
and
Wesołowska, Anna
2016.
Arylpiperazinylalkyl derivatives of 8-amino-1,3-dimethylpurine-2,6-dione as novel multitarget 5-HT/D receptor agents with potential antipsychotic activity.
Journal of Enzyme Inhibition and Medicinal Chemistry,
Vol. 31,
Issue. 6,
p.
1048.
Garay, Ricardo P.
Bourin, Michel
de Paillette, Evelyne
Samalin, Ludovic
Hameg, Ahcène
and
Llorca, Pierre-Michel
2016.
Potential serotonergic agents for the treatment of schizophrenia.
Expert Opinion on Investigational Drugs,
Vol. 25,
Issue. 2,
p.
159.
Towers, Christina G.
and
Thorburn, Andrew
2016.
Therapeutic Targeting of Autophagy.
EBioMedicine,
Vol. 14,
Issue. ,
p.
15.
Cronenwett, Will J.
2016.
Schizophrenia Pharmacology: Past, Present, and Future Targets for Intervention.
Focus,
Vol. 14,
Issue. 3,
p.
308.
de Bruin, N.M.W.J.
van Loevezijn, A.
Wicke, K.M.
de Haan, M.
Venhorst, J.
Lange, J.H.M.
de Groote, L.
van der Neut, M.A.W.
Prickaerts, J.
Andriambeloson, E.
Foley, A.G.
van Drimmelen, M.
van der Wetering, M.
and
Kruse, C.G.
2016.
The selective 5-HT 6 receptor antagonist SLV has putative cognitive- and social interaction enhancing properties in rodent models of cognitive impairment.
Neurobiology of Learning and Memory,
Vol. 133,
Issue. ,
p.
100.
Ivachtchenko, Alexandre V.
Lavrovsky, Yan
and
Ivanenkov, Yan A.
2016.
AVN-211, Novel and Highly Selective 5-HT6 Receptor Small Molecule Antagonist, for the Treatment of Alzheimer’s Disease.
Molecular Pharmaceutics,
Vol. 13,
Issue. 3,
p.
945.
Ivachtchenko, Alexandre V.
Okun, Ilya
Aladinskiy, Vladimir
Ivanenkov, Yan
Koryakova, Angela
Karapetyan, Ruben
Mitkin, Oleg
Salimov, Ramiz
Ivashchenko, Andrey
and
Bezprozvanny, Ilya
2017.
AVN-492, A Novel Highly Selective 5-HT6R Antagonist: Preclinical Evaluation.
Journal of Alzheimer's Disease,
Vol. 58,
Issue. 4,
p.
1043.
Matsumoto, Mitsuyuki
Walton, Noah M.
Yamada, Hiroshi
Kondo, Yuji
Marek, Gerard J.
and
Tajinda, Katsunori
2017.
The impact of genetics on future drug discovery in schizophrenia.
Expert Opinion on Drug Discovery,
Vol. 12,
Issue. 7,
p.
673.
Tang, Siu W.
Tang, Wayne H.
and
Leonard, Brian E.
2017.
Managing interactions between cognitive enhancers and other psychotropics.
International Clinical Psychopharmacology,
Vol. 32,
Issue. 4,
p.
175.
Morozova, Margarita
Burminskiy, Denis
Rupchev, George
Lepilkina, Taissia
Potanin, Sergey
Beniashvili, Allan
Lavrovsky, Yan
Vostokova, Natalia
and
Ivaschenko, Alexander
2017.
5-HT6 Receptor Antagonist as an Adjunct Treatment Targeting Residual Symptoms in Patients With Schizophrenia.
Journal of Clinical Psychopharmacology,
Vol. 37,
Issue. 2,
p.
169.
Radhakrishnan, Rajiv
Nabulsi, Nabeel
Gaiser, Edward
Gallezot, Jean-Dominique
Henry, Shannan
Planeta, Beata
Lin, Shu-fei
Ropchan, Jim
Williams, Wendol
Morris, Evan
D’Souza, Deepak Cyril
Huang, Yiyun
Carson, Richard E.
and
Matuskey, David
2018.
Age-Related Change in 5-HT6 Receptor Availability in Healthy Male Volunteers Measured with 11C-GSK215083 PET.
Journal of Nuclear Medicine,
Vol. 59,
Issue. 9,
p.
1445.
Sinkeviciute, Igne
Begemann, Marieke
Prikken, Merel
Oranje, Bob
Johnsen, Erik
Lei, Wan U.
Hugdahl, Kenneth
Kroken, Rune A.
Rau, Carina
Jacobs, Jolien D.
Mattaroccia, Silvia
and
Sommer, Iris E.
2018.
Efficacy of different types of cognitive enhancers for patients with schizophrenia: a meta-analysis.
npj Schizophrenia,
Vol. 4,
Issue. 1,
de Assis Brasil, Eduardo Silva
Guerino Furini, Cristiane Regina
da Silva Rodrigues, Fernanda
Nachtigall, Eduarda Godfried
Kielbovicz Behling, Jonny Anderson
Saenger, Bruna Freitas
Farias, Clarissa Penha
de Carvalho Myskiw, Jociane
and
Izquierdo, Ivan
2019.
The blockade of the serotoninergic receptors 5-HT5A, 5-HT6 and 5-HT7 in the basolateral amygdala, but not in the hippocampus facilitate the extinction of fear memory.
Behavioural Brain Research,
Vol. 372,
Issue. ,
p.
112055.
Hogendorf, Adam S.
Hogendorf, Agata
Kurczab, Rafał
Kalinowska-Tłuścik, Justyna
Popik, Piotr
Nikiforuk, Agnieszka
Krawczyk, Martyna
Satała, Grzegorz
Lenda, Tomasz
Knutelska, Joanna
Bugno, Ryszard
Staroń, Jakub
Pietruś, Wojciech
Matłoka, Mikołaj
Dubiel, Krzysztof
Moszczyński-Pętkowski, Rafał
Pieczykolan, Jerzy
Wieczorek, Maciej
Pilarski, Bogusław
Zajdel, Paweł
and
Bojarski, Andrzej J.
2019.
2-Aminoimidazole-based antagonists of the 5-HT6 receptor – A new concept in aminergic GPCR ligand design.
European Journal of Medicinal Chemistry,
Vol. 179,
Issue. ,
p.
1.
Bar-Yosef, Tamara
Damri, Odeya
and
Agam, Galila
2019.
Dual Role of Autophagy in Diseases of the Central Nervous System.
Frontiers in Cellular Neuroscience,
Vol. 13,
Issue. ,
Gyertyán, István
Kassai, Ferenc
Kozma, Kata
Kitka, Tamás
and
Ernyey, Aliz Judit
2020.
Procognitive profiling of a serotonin 5-HT6 receptor antagonist in a complex model system in rats: A novel translational approach for clinical prediction.
Brain Research Bulletin,
Vol. 165,
Issue. ,
p.
238.
Tsegay, Etsay Weldekidan
Demise, Desalegn Getnet
Hailu, Nigus Alemu
and
Gufue, Zenawi Hagos
2020.
<p>Serotonin Type 6 and 7 Receptors as a Novel Therapeutic Target for the Treatment of Schizophrenia</p>.
Neuropsychiatric Disease and Treatment,
Vol. Volume 16,
Issue. ,
p.
2499.
Radhakrishnan, Rajiv
Matuskey, David
Nabulsi, Nabeel
Gaiser, Edward
Gallezot, Jean-Dominique
Henry, Shannan
Planeta, Beata
Lin, Shu-fei
Ropchan, Jim
Huang, Yiyun
Carson, Richard E
and
D'Souza, Deepak Cyril
2020.
In vivo 5-HT6 and 5-HT2A receptor availability in antipsychotic treated schizophrenia patients vs. unmedicated healthy humans measured with [11C]GSK215083 PET.
Psychiatry Research: Neuroimaging,
Vol. 295,
Issue. ,
p.
111007.